News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Review: Henry Rollins Burning Down The House

With his lantern jaw, close-cropped hair, and muscle-bound physique, Henry Rollins could not be further from the US Marine image his appearance might suggest. More>>

A Series Of Tubes: 150 Years Of The Cook Strait Cable

“It was a momentous achievement for its time. The successful connection came on the third attempt at laying the cable, and followed a near disaster when the first cable snapped - almost destroying the ship Weymouth in the process,” says Ms Adams. More>>

ALSO:

February 2017: Guns N' Roses - New Zealand Dates Announced

Founder Axl Rose and former members, Slash and Duff McKagan have regrouped for one of the century’s most anticipated tours... Rolling Stone said: "This was the real thing, the thing we'd all been waiting for: the triumphant return of one of the most important bands to cross rock music history. And it happened in our lifetime.” More>>

Werewolf: Brando, Peckinpah And Billy The Kid

Gordon Campbell: Initially, One-Eyed Jacks was supposed to have been directed by Stanley Kubrick from a script by Sam Peckinpah – yet it quickly became Brando’s baby... More>>

Book Awards: ANZAC Heroes Wins Margaret Mahy Book Of The Year

“Simply stunning, with gold-standard production values,” say the judges of the winner of this year’s Margaret Mahy Book of the Year Award in the prestigious New Zealand Book Awards for Children and Young Adults. ANZAC Heroes is also the winner of the Elsie Locke Award for the Best Book in the Non-Fiction category. More>>

Baby Animals: Hamilton Zoo Rhino Calf Named

Hamilton Zoo’s latest rhino calf has been named Samburu and he's being celebrated with a unique zoo experience... Samburu arrived after his mother Kito’s 16-month pregnancy and the calf brings the number of white rhinos at Hamilton Zoo to six. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news